Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 4-(Aminosulfonyl)-N-[(2,4,6-Trifluorophenyl)Methyl]-Benzamide is a synthetic small molecule compound with the molecular formula C14H11F3N2O3S and a molecular weight of approximately 344.31 g/mol[1][2][3]. It is classified as a benzamide derivative containing both sulfonamide and trifluoromethyl functional groups. This compound has been studied primarily as an experimental inhibitor of carbonic anhydrase II (CA II), an enzyme involved in the reversible hydration of carbon dioxide[2][6]. Structural studies have shown it binds tightly to CA II (Kd ~3.9 nM), making it a potent inhibitor[2][6]. The compound has not been approved for any therapeutic use and remains at the experimental stage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(aminosulfonyl)-n-[(2,4,6-trifluorophenyl)methyl]-benzamide.